NPNathan W. Pearlman

Nathan W. Pearlman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nathan W. Pearlman has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association of sentinel lymph node diameter with melanoma metastasis

    by Justin Merkow, Alessandro Paniccia, Edward Jones, Teresa Jones, Maggie Hodges, Robert Stovall, Nicole Kounalakis, Csaba Gajdos, Karl Lewis, William Robinson, et al.


  • SPECT/CT Improves Detection of Metastatic Sentinel Lymph Nodes in Patients with Head and Neck Melanoma

    by Brandon C. Chapman, Ana Gleisner, Jennifer J. Kwak, Patrick Hosokawa, Alessandro Paniccia, Justin S. Merkow, Phillip J. Koo, Csaba Gajdos, Nathan W. Pearlman, Martin D. McCarter, et al.

    A positive sentinel lymph node (SLN) is the most important prognostic factor for predicting survival in cutaneous melanoma. This study aimed to evaluate how the addition of single-photon emission computed tomography (SPECT) and computed tomography (CT) to planar lymphoscintigraphy (PL) alters SLN identification, yield, and localization of metastatic nodes in head and neck melanoma. This retrospective review examined patients undergoing SLN biopsy for cutaneous melanoma of the head and neck between July 2003 and December 2015. Patient demographics and pathologic outcomes were compared for patients undergoing SPECT-CT versus PL. A multivariable logistic regression analysis was used to identify factors associated with the identification of a positive SLN. Among 176 patients undergoing SLN biopsy, 91 underwent PL and 85 underwent SPECT-CT and PL. The patients in the SPECT-CT group were older than the PL patients (p = 0.050) but the groups did not differ in gender (p = 0.447), Breslow thickness (p = 0.744), or total number of SLNs identified (p = 0.633). As shown by the multivariate regression analysis, only Breslow thickness [odds ratio (OR) 1.47; 95 % confidence interval (CI) 1.17-1.84] and SPECT-CT (OR 3.58; 95 % CI 1.24-10.4) were associated with a positive SLN. The use of SPECT-CT for patients with head and neck cutaneous melanoma significantly increases the likelihood of retrieving a positive SLN. Long-term follow-up evaluation is needed for further definition of the impact that SPECT-CT has on recurrence and survival.


  • Smaller pelvic volume is associated with postoperative infection after pelvic salvage surgery for recurrent malignancy

    by Edward L. Jones, Teresa S. Jones, Alessandro Paniccia, Justin S. Merkow, Daniel M. Wells, Nathan W. Pearlman, Martin D. McCarter


  • Open Access

    Sequential radiofrequency ablation and surgical debulking for unresectable colorectal carcinoma: Thermo‐surgical ablation

    by R. Taylor Ripley, Csaba Gajdos, Amy E. Reppert, Tracey MacDermott, Martin D. McCarter, Nathan W. Pearlman

    Background and Objectives: Despite decreasing frequency, local recurrences of unresectable colorectal cancer (CRC) remain difficult problems. These patients have few treatment options with conventional therapy. Preliminary results of sequential radiofrequency ablation (RFA) and surgical debulking (thermo‐surgical ablation) suggest this technique may have benefit.Methods: We reviewed a prospective database of patients undergoing thermo‐surgical ablation for unresectable colorectal carcinoma from 2003 to 2011.Results: Sixteen patients were treated with unresectable, recurrent abdomino‐pelvic colorectal carcinoma: 11 in pelvis; 4 with isolated aortic/retroperitoneal disease; and 1 with pelvic and peri‐adrenal/retroperitoneal disease. Eleven patients had recurrent rectal cancer and five had recurrent colon cancer.Median overall and 3‐year actuarial survivals were 15 months and 24%, respectively. Median and 3‐year PFS was 12 months and 19%, respectively. Three patients without disease have survived 0.75, 4.0, and 7.0 years. Two patients died at 5.0 and 5.5 years. A disease‐free interval (DFI) of >24 months after initial resection was associated with longer overall survival (60 months vs. 4 months; P = 0.001).Conclusions: Thermo‐surgical debulking appears to have a role in the treatment of some patients with recurrent, unresectable CRC; those patients with DFI >24 months after initial surgery benefited the most. J. Surg. Oncol. 2013;107:144–147.